18:08 , Dec 7, 2018 |  BC Week In Review  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
00:27 , Dec 4, 2018 |  BC Extra  |  Company News

argenx gets $500M up front from Janssen for CD70 mAb

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) will receive $500 million up front from Janssen Pharmaceuticals Inc. in exchange for exclusive, worldwide rights to anti-CD70 mAb cusatuzumab (ARGX-110). The upfront payment comprises $300 million in cash from the...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
20:41 , Oct 5, 2018 |  BC Week In Review  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
23:52 , Oct 1, 2018 |  BC Extra  |  Company News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
17:35 , Sep 28, 2018 |  BC Week In Review  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Sept. 26, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400...
20:07 , Sep 26, 2018 |  BC Extra  |  Company News

Syntimmune deal helps Alexion diversify beyond Soliris

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) took another step towards breaking its dependence on Soliris eculizumab on Wednesday, when it announced it will acquire rare autoimmune disease company Syntimmune Inc. (Boston, Mass.). Alexion will pay $400 million...
16:38 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

argenx planning Phase III for thrombocytopenia therapy

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said it plans to start Phase III testing of IV efgartigimod (ARGX-113) to treat primary immune thrombocytopenia (ITP) after reporting that the compound led to clinically meaningful platelet count improvements in...
16:30 , Sep 21, 2018 |  BC Week In Review  |  Financial News

argenx prices $300M follow-on

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) raised $300.6 million in a follow-on that priced after hours on Sept. 18. argenx sold 3.5 million ADSs at $86.50, an 8% discount to its NASDAQ close of $93.77 on Sept....
17:34 , Sep 19, 2018 |  BC Extra  |  Financial News

argenx, G1 price follow-ons, CRISPR proposes

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) and G1 Therapeutics Inc. (NASDAQ:GTHX) raised $300.6 million and $180 million, respectively, in follow-ons that priced after hours Tuesday. argenx sold 3.5 million ADSs at $86.50, an 8% discount to its...